KRAS and colorectal adenocarcinoma: Clinical activity of sotorasib and adagrasib is unprecedented given that patients with KRAS mutant lung or colorectal adenocarcinomas had no or only limited access to targeted therapies as KRAS mutation is a negative predictive factor for all anti-EGFR therapies [12, 13].